10-Q: Safety Shot Inc. Reports Q2 2024 Results, Revenue Growth Offset by Increased Expenses

Safety Shot Inc. saw a significant increase in revenue in the second quarter of 2024, driven by the launch of its Safety Shot Dietary Supplement, but also experienced a substantial net loss due to increased operating expenses and a one-time inventory write-off.

Summary

• Safety Shot Inc. reported a net loss of $23.9 million for the six months ended June 30, 2024, compared to a net loss of $1.7 million for the same period in 2023.
• The company's revenue increased significantly to $880,972 for the first six months of 2024, up from $58,093 in the same period of 2023, primarily due to the launch of the Safety Shot Dietary Supplement in December 2023.
• Cost of sales also increased substantially to $2.9 million, including a $1.6 million write-down of inventory due to rebranding issues.
• Operating expenses surged to $21.6 million, driven by marketing, legal, professional fees, and stock-based compensation.
• The company's cash balance decreased to $3.2 million as of June 30, 2024, from $3.8 million at the end of 2023.
• The company has ongoing legal proceedings and has been issued a going concern warning by its auditors.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with strong revenue growth offset by significant losses, high expenses, and a going concern warning. The ongoing legal issues and need for additional capital further contribute to a negative sentiment.

Positives

• The company experienced a significant increase in revenue due to the launch of its Safety Shot Dietary Supplement.
• The company is actively pursuing new product lines, including a powdered stick pack and a four-ounce version of the Safety Shot Dietary Supplement.
• The company has completed clinical trials of the Safety Shot Dietary Supplement, showing a statistically significant reduction in BAC of participants.

Negatives

• The company incurred a substantial net loss of $23.9 million for the six months ended June 30, 2024.
• Operating expenses increased significantly to $21.6 million, driven by marketing, legal, professional fees, and stock-based compensation.
• The company recorded a one-time inventory write-off of $1.6 million due to rebranding issues.
• The company's cash balance decreased to $3.2 million as of June 30, 2024.
• The company has ongoing legal proceedings and has been issued a going concern warning by its auditors.

Risks

• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is involved in multiple legal proceedings, which could result in significant financial liabilities.
• The company's reliance on third-party manufacturers and suppliers poses risks to its supply chain.
• The company's products are subject to extensive government regulation, and failure to comply could result in penalties.
• The company may need to raise additional capital, which could dilute existing shareholders' equity.
• The company's success depends on its ability to develop and maintain its brand and reputation.

Future Outlook

The company intends to continue its current product lines and develop new flavors and dosages for its products. They also plan to expand their product offerings to include a powdered stick pack and a four-ounce version of the Safety Shot Dietary Supplement. The company is also speaking with Big Box stores with the intention to launch in the second quarter of 2024.

Management Comments

• The Safety Shot Dietary Supplement has been formulated to reduce the accumulation of blood alcohol content by supporting its metabolism.
• The Safety Shot Dietary Supplement comprises 28 active ingredients, all falling under the Generally Regarded As Safe (GRAS) category.
• The Safety Shot Dietary Supplement is currently manufactured in a facility adhering to Good Manufacturing Practices (GMP).
• The company is committed to driving continuous improvement through innovation.
• The company believes that the Safety Shot Dietary Supplement stands as a unique product in the liquid dietary supplement market.

Industry Context

The company operates in the competitive health and wellness market, facing competition from numerous companies involved in the production of health and welfare products. The company's focus on a liquid dietary supplement for reducing blood alcohol content positions it in a niche market within the broader health and wellness industry. The company is also subject to increasing regulatory scrutiny regarding the marketing and labeling of functional foods and dietary supplements.

Comparison to Industry Standards

• The company's revenue growth is notable compared to its previous performance, but its significant net loss and high operating expenses are concerning when compared to established companies in the health and wellness sector.
• The company's reliance on third-party manufacturers is common in the industry, but the company's lack of control over these manufacturers poses a risk.
• The company's ongoing legal proceedings are a significant concern and are not typical for companies of this size in the health and wellness industry.
• The company's going concern warning from its auditors is a serious issue and is not typical for companies with a similar revenue profile.

Legal Proceedings

• Intracoastal Capital, LLC filed a lawsuit against the Company alleging breach of a common stock warrant.
• Sabby Volatility Warrant Master Fund Ltd. filed a lawsuit against the Company alleging breach-of-contact, promissory estoppel, and negligent misrepresentation related to a delayed spin-off.
• Sabby Volatility Warrant Master Find Ltd. sued the Company for improperly refusing to honor the exercise of a warrant.
• 3i LP filed a lawsuit against the Company for alleged denial of an attempt to exercise certain warrants.
• Bigger Capital fund, L.P. filed a lawsuit against the Company for breach of contract related to a warrant.
• Alta Partners, LLC filed a lawsuit against the Company for breach of contract related to a warrant.

Stakeholder Impact

• Shareholders face significant risk due to the company's substantial losses, going concern warning, and potential dilution from future capital raises.
• Employees may be concerned about the company's financial stability and the potential for job losses.
• Customers may be concerned about the company's ability to continue producing and delivering its products.
• Suppliers may be concerned about the company's ability to pay its bills.
• Creditors face increased risk due to the company's financial instability and ongoing legal proceedings.

Next Steps

• The company plans to continue to develop new flavors for each of its current SKUs (12oz., 4 oz. and Stick Pack).
• The company plans to continue to develop new formulations for its products.
• The company plans to continue to develop new dosages for its products.
• The company plans to continue to conduct research studies addressing dose, ingredient selection and efficacy across multiple indications.
• The company is currently speaking with Big Box stores with the intention to launch in the second quarter of 2024.

Key Dates

Keywords

Safety Shot, Dietary Supplement, Revenue, Net Loss, Operating Expenses, Clinical Trials, Legal Proceedings, Going Concern, Warrants, Stock Based Compensation